| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Sergliflozin etabonate is a prodrug that is converted to the active form, sergliflozin, upon absorption. The active metabolite selectively inhibits SGLT2. It is a potent inhibitor of hSGLT2 with an IC50 of 7.5 nM, demonstrating >200-fold selectivity over hSGLT1. By inhibiting SGLT2, it reduces renal glucose reabsorption, leading to increased urinary glucose excretion and lower blood glucose levels.
|
|---|---|
| ln Vitro |
In vitro, Sergliflozin etabonate is a potent inhibitor of SGLT2 with an IC50 of 7.5 nM for hSGLT2. It shows >200-fold selectivity over hSGLT1. As a prodrug, it is converted to the active sergliflozin, which exerts the inhibitory effect.
|
| ln Vivo |
In KK-Ay mice, sergliflozin etabonate (1, 3, 10, 30 mg/kg; non-threshold; once) dramatically and dose-dependently decreased fasting blood glucose levels [1]. The triglyceride content in KK-Ay mice is decreased by sergliflozin etabonate (1.7, 8.4, 45.7 mg/kg containing 0.001, 0.005, and 0.025% sergliflozin etabonate in feed; meal; daily for 9 weeks). This reduction in blood glucose levels occurs both during non-fasting and during the formulation-dependent phase.
In vivo, Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Its antidiabetic and antihyperglycemic effects have been demonstrated in animal models. Upon oral administration, it is converted to sergliflozin, which inhibits SGLT2 and promotes glucosuria. |
| Enzyme Assay |
In vitro enzyme assays for Sergliflozin etabonate are not directly applicable, as it is a prodrug. The activity of its active metabolite, sergliflozin, is assessed by measuring the inhibition of SGLT2-mediated glucose transport. Cells expressing human SGLT2 are incubated with radiolabeled glucose in the presence of the compound, and the inhibition of glucose uptake is measured.
|
| Cell Assay |
In vitro cellular assays for Sergliflozin etabonate are performed using cell lines expressing SGLT2. Cells are treated with the compound, and glucose uptake is measured. The compound's ability to inhibit glucose transport is quantified.
|
| Animal Protocol |
Animal/Disease Models: 14 weeks, female KK-Ay mice [1]
Doses: 1, 3, 10, 30mg/kg Route of Administration: oral;. Experimental Results: The blood glucose levels in the 1 mg/kg group, 3 mg/kg group, 10 mg/kg group, and 30 mg/kg group were Dramatically diminished 2 hrs (hrs (hours)) after administration, and the non-fasting blood glucose levels were Dramatically diminished. 12%, 15%, 28% and 39% respectively. Animal/Disease Models: 4 weeks, female KK-Ay mice [1] Doses: 0.001, 0.005 and 0.025% Seragliflozin etabonate 1.7, 8.4, 45.7 mg/kg Route of Administration: Daily feeding for 9 weeks Experimental Results: Non Fasting blood glucose levels and triglyceride content in the liver were diminished in a dose-dependent manner in diabetic control KK-Ay mice. In vivo animal studies for Sergliflozin etabonate are conducted in mouse models of diabetes, such as db/db or streptozotocin-induced diabetic mice. The compound is administered orally, and blood glucose levels are measured over time. Urinary glucose excretion is also assessed to confirm the mechanism of action. |
| ADME/Pharmacokinetics |
Sergliflozin etabonate is an orally active prodrug. Upon oral administration, it is absorbed and converted to the active sergliflozin. Its PK properties support once-daily dosing.
|
| Toxicity/Toxicokinetics |
Toxicological data for Sergliflozin etabonate are not detailed in publicly available sources. As a compound that has been investigated clinically, it would have undergone standard preclinical safety assessments.
|
| References | |
| Additional Infomation |
Etabonate is a glycoside antibiotic. It is a benzylphenol glucoside and a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor with hypoglycemic activity. Its prodrug form, epoxetine, can be taken orally and is converted to epoxetine after absorption.
Sergliflozin etabonate is also known as GW869682X. It is a prodrug of sergliflozin, a selective SGLT2 inhibitor. It has been investigated for the treatment of diabetes. Its development status may be discontinued. |
| Molecular Formula |
C23H28O9
|
|---|---|
| Molecular Weight |
448.46
|
| Exact Mass |
448.173
|
| CAS # |
408504-26-7
|
| Related CAS # |
408504-26-7 (etabonate);360775-96-8;
|
| PubChem CID |
9824918
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
611.5±55.0 °C at 760 mmHg
|
| Flash Point |
206.8±25.0 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.581
|
| LogP |
3.62
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
32
|
| Complexity |
566
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CCOC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@H](OC2=CC=CC=C2CC3=CC=C(C=C3)OC)O1)O)O)O
|
| InChi Key |
QLXKHBNJTPICNF-QMCAAQAGSA-N
|
| InChi Code |
InChI=1S/C23H28O9/c1-3-29-23(27)30-13-18-19(24)20(25)21(26)22(32-18)31-17-7-5-4-6-15(17)12-14-8-10-16(28-2)11-9-14/h4-11,18-22,24-26H,3,12-13H2,1-2H3/t18-,19-,20+,21-,22-/m1/s1
|
| Chemical Name |
ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[(4-methoxyphenyl)methyl]phenoxy]oxan-2-yl]methyl carbonate
|
| Synonyms |
KGT-1251; GW-869682X; GW-869682
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2299 mL | 11.1493 mL | 22.2985 mL | |
| 5 mM | 0.4460 mL | 2.2299 mL | 4.4597 mL | |
| 10 mM | 0.2230 mL | 1.1149 mL | 2.2299 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
